Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057377 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL27678259 | 0.95 | LOXL2 (0.54) | LOXL2TDP1HRH1CYP1A2CYP3A4 | |
| Bromide SCHEMBL27820627 | 0.92 | LOXL2 (0.52) | LOXL2TDP1HRH1CYP1A2CYP3A4 | |
| Bromide SCHEMBL1428221 | 0.85 | HRH1 (0.54) | LOXL2TDP1HRH1CYP1A2CYP3A4 | |
| Bromide SCHEMBL7919282 | 0.83 | HRH1 (0.57) | LOXL2TDP1HRH1CYP1A2CYP3A4 | |
| SCHEMBL708837 | 0.82 | HRH1 (0.56) | LOXL2TDP1HRH1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL8329183 | 0.80 | HRH1 (0.54) | LOXL2TDP1HRH1CYP1A2CYP3A4 | |
| SCHEMBL10376892 | 0.80 | HRH1 (0.59) | LOXL2TDP1HRH1CYP1A2CYP3A4 | |
| SCHEMBL151822 | 0.80 | LOXL2 (0.68) | LOXL2TDP1HRH1CYP1A2CYP3A4 | |
| SCHEMBL7740622 | 0.78 | HRH1 (0.63) | LOXL2TDP1HRH1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2024-10-31 | — | — | US | disclosed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023004376-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| CN-104039791-B | [1, 2, 3] triazolo [4, 5-D ] pyrimidine derivatives as cannabinoid receptor 2 agonists | 霍夫曼-拉罗奇有限公司 | 2016-11-09 | — | — | CN | disclosed |
| EP-2872501-B1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING SA (CH) | 2016-06-01 | — | — | EP | disclosed |
| CN-103930426-B | As [1,2,3] triazols [4, the 5-D] pyrimidine derivatives of Cannabined receptor 2 activators | HOFFMAN-LA ROCHE LTD. (CH) | 2016-05-11 | — | — | CN | disclosed |
| CN-104066732-B | Novel antiviral Pyrrolopyridine derivatives and preparation method thereof | KOREA CHEMICAL RESEARCH INSTITUTE (KR) | 2016-04-13 | — | — | CN | disclosed |
| CN-103502237-B | Faah inhibitor | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-01-20 | — | — | CN | disclosed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | disclosed |
| CN-1759117-A | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC (JP) | 2006-04-12 | — | — | CN | disclosed |
| CN-1723196-A | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2006-01-18 | — | — | CN | disclosed |
| CN-1610666-A | Benzamidine derivative | SANKYO CO (JP) | 2005-04-27 | — | — | CN | disclosed |
| CN-1602311-A | Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO-synthase | AVENTIS PHARMA SA (FR) | 2005-03-30 | — | — | CN | disclosed |
| CN-1133625-C | Quinazoline derivatives | — | 2004-01-07 | — | — | CN | disclosed |
| EP-0993442-B1 | HYDRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6235787-B1 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; BONE DISORDERS; SKIN DISORDERS; MULTIPLE SCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-05-22 | — | — | US | disclosed |
| EP-0993442-A1 | HYDRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-04-19 | — | — | EP | disclosed |
| CN-1205694-A | Quinazoline derivatives | ZENECA LTD (GB) | 1999-01-20 | — | — | CN | disclosed |
| WO-1999001428-A1 | HYDRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | LOXL2 2985/4885TDP1 818/4885HRH1 4403/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | LOXL2 2965/4885TDP1 1726/4885HRH1 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.